Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing

Matthias Götte

doi:10.1371/journal.pmed.0040346

Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing

PLoS Med. 2007 Dec;4(12):e346. doi: 10.1371/journal.pmed.0040346.

Author

Matthias Götte¹

Affiliation

¹ Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada. matthias.gotte@mcgill.ca

Abstract

The author discusses a new study that found a common mutation in the connection domain of reverse transcriptase, a mutation that confers resistance to two antiretroviral drug classes.

Publication types

Comment

MeSH terms

Drug Resistance, Multiple, Viral / genetics*
Genetic Testing*
Genotype
HIV Infections / diagnosis
HIV Infections / drug therapy*
HIV Infections / virology
HIV Reverse Transcriptase / antagonists & inhibitors*
HIV Reverse Transcriptase / chemistry
HIV Reverse Transcriptase / genetics
HIV Reverse Transcriptase / metabolism
HIV-1 / drug effects*
HIV-1 / enzymology
HIV-1 / genetics
Humans
Mutation*
Nevirapine / therapeutic use
Patient Selection*
Phenotype
Protein Structure, Tertiary
Reverse Transcriptase Inhibitors / pharmacology
Reverse Transcriptase Inhibitors / therapeutic use*
Time Factors
Treatment Outcome
Viral Load
Zidovudine / therapeutic use

Substances

Reverse Transcriptase Inhibitors
Zidovudine
Nevirapine
reverse transcriptase, Human immunodeficiency virus 1
HIV Reverse Transcriptase